Axovant Sciences Ltd. (NYSE:AXON) has earned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $28.17.

Several equities analysts have commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $31.00 price objective on shares of Axovant Sciences in a report on Friday, June 9th. CIBC upped their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday. Oppenheimer Holdings, Inc. upped their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 9th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price objective (up previously from $22.00) on shares of Axovant Sciences in a research report on Tuesday, June 13th.

In related news, Director W Anthony Vernon acquired 53,937 shares of Axovant Sciences stock in a transaction dated Monday, April 17th. The stock was bought at an average price of $18.54 per share, with a total value of $999,991.98. Following the transaction, the director now directly owns 53,937 shares in the company, valued at approximately $999,991.98. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Hung bought 539,375 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The stock was purchased at an average price of $18.54 per share, for a total transaction of $10,000,012.50. Following the completion of the acquisition, the insider now owns 539,375 shares in the company, valued at $10,000,012.50. The disclosure for this purchase can be found here. Corporate insiders own 3.10% of the company’s stock.

Several institutional investors have recently modified their holdings of AXON. Candriam Luxembourg S.C.A. boosted its position in shares of Axovant Sciences by 77.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 160,000 shares of the biotechnology company’s stock valued at $2,391,000 after buying an additional 70,000 shares during the period. Woodstock Corp boosted its position in shares of Axovant Sciences by 55.0% in the first quarter. Woodstock Corp now owns 35,003 shares of the biotechnology company’s stock valued at $523,000 after buying an additional 12,417 shares during the period. Teachers Advisors LLC boosted its position in shares of Axovant Sciences by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock valued at $513,000 after buying an additional 2,038 shares during the period. Norges Bank bought a new position in shares of Axovant Sciences during the fourth quarter valued at $508,000. Finally, Artal Group S.A. boosted its position in shares of Axovant Sciences by 20.0% in the fourth quarter. Artal Group S.A. now owns 300,000 shares of the biotechnology company’s stock valued at $3,726,000 after buying an additional 50,000 shares during the period.

Axovant Sciences (NYSE AXON) traded up 1.50% during mid-day trading on Friday, reaching $21.03. 512,248 shares of the company’s stock traded hands. The company’s market capitalization is $2.26 billion. The company has a 50-day moving average of $22.55 and a 200-day moving average of $16.39. Axovant Sciences has a 52-week low of $11.01 and a 52-week high of $25.18.

Axovant Sciences (NYSE:AXON) last issued its earnings results on Tuesday, June 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.02. Equities research analysts expect that Axovant Sciences will post ($2.11) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Axovant Sciences Ltd. (AXON) Receives Consensus Rating of “Buy” from Brokerages” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/06/18/axovant-sciences-ltd-axon-given-consensus-recommendation-of-buy-by-brokerages-updated-updated-updated.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.